Cargando…

The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts

INTRODUCTION: Cardiometabolic syndrome (CMS), as a bunch of metabolic disorders mainly characterized by type 2 diabetes mellitus (T2DM), hypertension, atherosclerosis, central adiposity, and abdominal obesity triggering androgen deficiency, is one of the most critical threats to men. Although many s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirlangic, Omer Faruk, Yilmaz-Oral, Didem, Kaya-Sezginer, Ecem, Toktanis, Gamze, Tezgelen, Aybuke Suveyda, Sen, Ekrem, Khanam, Armagan, Oztekin, Cetin Volkan, Gur, Serap
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261691/
https://www.ncbi.nlm.nih.gov/pubmed/32201216
http://dx.doi.org/10.1016/j.esxm.2020.02.006
_version_ 1783540542586486784
author Kirlangic, Omer Faruk
Yilmaz-Oral, Didem
Kaya-Sezginer, Ecem
Toktanis, Gamze
Tezgelen, Aybuke Suveyda
Sen, Ekrem
Khanam, Armagan
Oztekin, Cetin Volkan
Gur, Serap
author_facet Kirlangic, Omer Faruk
Yilmaz-Oral, Didem
Kaya-Sezginer, Ecem
Toktanis, Gamze
Tezgelen, Aybuke Suveyda
Sen, Ekrem
Khanam, Armagan
Oztekin, Cetin Volkan
Gur, Serap
author_sort Kirlangic, Omer Faruk
collection PubMed
description INTRODUCTION: Cardiometabolic syndrome (CMS), as a bunch of metabolic disorders mainly characterized by type 2 diabetes mellitus (T2DM), hypertension, atherosclerosis, central adiposity, and abdominal obesity triggering androgen deficiency, is one of the most critical threats to men. Although many significant preclinical and clinical findings explain CMS, new approaches toward common pathophysiological mechanisms and reasonable therapeutic targets are lacking. AIM: To gain a further understanding of the role of androgen levels in various facets of CMS such as the constellation of cardiometabolic risk factors including central adiposity, dyslipidemia, insulin resistance, diabetes, and arterial hypertension and to define future directions for development of effective therapeutic modalities. METHODS: Clinical and experimental data were searched through scientific literature databases (PubMed) from 2009 to October 2019. MAIN OUTCOME MEASURE: Evidence from basic and clinical research was gathered with regard to the causal impact and therapeutic roles of androgens on CMS. RESULTS: There are important mechanisms implicated in androgen levels and the risk of CMS. Low testosterone levels have many signs and symptoms on cardiometabolic and glycometabolic risks as well as abdominal obesity in men. CLINICAL IMPLICATIONS: The implications of the findings can shed light on future improvements in androgen levels and add potentially predictive risk for CMS, as well as T2DM, abdominal obesity to guide clinical management in the early stage. STRENGTHS & LIMITATIONS: This comprehensive review refers to the association between androgens and cardiovascular health. A limitation of this study is the lack of large, prospective population-based studies that analyze the effects of testosterone treatment on CMS or mortality. CONCLUSION: Low testosterone levels have several common features with metabolic syndrome. Thus, testosterone may have preventive role in the progress of metabolic syndrome and subsequent T2DM, abdominal obesity, and cardiovascular disease and likely affect aging men's health mainly through endocrine and vascular mechanisms. Further studies are necessary to evaluate the therapeutic interventions directed at preventing CMS in men. Kirlangic OF, Yilmaz-Oral D, Kaya-Sezginer E, et al. The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts. Sex Med 2020;8:132–155.
format Online
Article
Text
id pubmed-7261691
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72616912020-06-01 The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts Kirlangic, Omer Faruk Yilmaz-Oral, Didem Kaya-Sezginer, Ecem Toktanis, Gamze Tezgelen, Aybuke Suveyda Sen, Ekrem Khanam, Armagan Oztekin, Cetin Volkan Gur, Serap Sex Med Review INTRODUCTION: Cardiometabolic syndrome (CMS), as a bunch of metabolic disorders mainly characterized by type 2 diabetes mellitus (T2DM), hypertension, atherosclerosis, central adiposity, and abdominal obesity triggering androgen deficiency, is one of the most critical threats to men. Although many significant preclinical and clinical findings explain CMS, new approaches toward common pathophysiological mechanisms and reasonable therapeutic targets are lacking. AIM: To gain a further understanding of the role of androgen levels in various facets of CMS such as the constellation of cardiometabolic risk factors including central adiposity, dyslipidemia, insulin resistance, diabetes, and arterial hypertension and to define future directions for development of effective therapeutic modalities. METHODS: Clinical and experimental data were searched through scientific literature databases (PubMed) from 2009 to October 2019. MAIN OUTCOME MEASURE: Evidence from basic and clinical research was gathered with regard to the causal impact and therapeutic roles of androgens on CMS. RESULTS: There are important mechanisms implicated in androgen levels and the risk of CMS. Low testosterone levels have many signs and symptoms on cardiometabolic and glycometabolic risks as well as abdominal obesity in men. CLINICAL IMPLICATIONS: The implications of the findings can shed light on future improvements in androgen levels and add potentially predictive risk for CMS, as well as T2DM, abdominal obesity to guide clinical management in the early stage. STRENGTHS & LIMITATIONS: This comprehensive review refers to the association between androgens and cardiovascular health. A limitation of this study is the lack of large, prospective population-based studies that analyze the effects of testosterone treatment on CMS or mortality. CONCLUSION: Low testosterone levels have several common features with metabolic syndrome. Thus, testosterone may have preventive role in the progress of metabolic syndrome and subsequent T2DM, abdominal obesity, and cardiovascular disease and likely affect aging men's health mainly through endocrine and vascular mechanisms. Further studies are necessary to evaluate the therapeutic interventions directed at preventing CMS in men. Kirlangic OF, Yilmaz-Oral D, Kaya-Sezginer E, et al. The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts. Sex Med 2020;8:132–155. Elsevier 2020-03-20 /pmc/articles/PMC7261691/ /pubmed/32201216 http://dx.doi.org/10.1016/j.esxm.2020.02.006 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Kirlangic, Omer Faruk
Yilmaz-Oral, Didem
Kaya-Sezginer, Ecem
Toktanis, Gamze
Tezgelen, Aybuke Suveyda
Sen, Ekrem
Khanam, Armagan
Oztekin, Cetin Volkan
Gur, Serap
The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
title The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
title_full The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
title_fullStr The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
title_full_unstemmed The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
title_short The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
title_sort effects of androgens on cardiometabolic syndrome: current therapeutic concepts
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261691/
https://www.ncbi.nlm.nih.gov/pubmed/32201216
http://dx.doi.org/10.1016/j.esxm.2020.02.006
work_keys_str_mv AT kirlangicomerfaruk theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT yilmazoraldidem theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT kayasezginerecem theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT toktanisgamze theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT tezgelenaybukesuveyda theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT senekrem theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT khanamarmagan theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT oztekincetinvolkan theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT gurserap theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT kirlangicomerfaruk effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT yilmazoraldidem effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT kayasezginerecem effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT toktanisgamze effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT tezgelenaybukesuveyda effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT senekrem effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT khanamarmagan effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT oztekincetinvolkan effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts
AT gurserap effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts